FormFactor Q3 2026 Results Exceed Outlook, But Valuation Risks Remain

What happened

FormFactor reported Q3 2026 results with revenue, gross margin, and EPS exceeding the high end of its guidance, driven by continued strong broad-based demand across its probe-card segments. The company highlighted robust orders from both Foundry & Logic and DRAM, reflecting sustained AI and HBM-related test demand. This positive update follows the FQ2'26 profitability step-up and indicates that operational execution, including the Texas factory ramp and restructuring, is on track. However, the stock remains richly valued, with prior analysis showing high P/E and EV/EBITDA multiples and limited margin of safety, so the good news may already be priced in. Key risks persist, including customer concentration (SK hynix at ~30% of revenue), potential tariff impacts, and the timing of HBM4/HBM4E volume ramps, which could introduce volatility despite near-term strength.

Implication

Investors should recognize that while the Q3 beat is a positive signal, the stock may have already priced in much of the good news, as evidenced by its high valuation multiples. The continued broad-based demand reduces the near-term risk of a sharp revenue slowdown, but customer concentration and the timing of next-generation HBM ramps remain key swing factors. The margin expansion story is still subject to tariff impacts and restructuring costs, so monitoring gross margin sustainability is crucial. If the stock has rallied significantly on this news, it may be prudent to take profits or avoid adding at these levels, waiting for a pullback toward the previously identified attractive entry around $110. Conversely, if the market reaction is muted due to valuation concerns, that could signal that the stock is discounting the risks, but the original WAIT rating suggests waiting for more clarity on Texas ramp and Systems stabilization before turning more constructive.

Thesis delta

The Q3 beat and continued strong demand provide evidence that the underlying business momentum is intact, which reduces the probability of the near-term downside scenario. However, the core thesis remains unchanged because the valuation already embeds high growth expectations and a sustained margin step-up, and the key risks around HBM4 timing, customer concentration, and tariff drag are not resolved by one quarter's results. Therefore, the WAIT rating is maintained, with the positive results nudging confidence slightly higher but not enough to shift to a buy without a more attractive entry point.